B2 Prognostic Score: External Validation of a Clinical Decision-making Tool for Metastatic Breast Cancer

• Published in: Clinical breast cancer Vol. 19; no. 5; pp. 333 - 339
• Main Authors: Stueber, Tanja Nadine, Wischnewsky, Manfred, Leinert, Elena, Diessner, Joachim, Bartmann, Catharina, Stein, Roland Gregor, Woeckel, Achim
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-10-2019
• Subjects: Intrinsic subgroups; Metastatic breast cancer; Prognostic score; Survival; Metastatic breast cancer; Intrinsic subgroups; Survival; Prognostic score
• ISSN: 1526-8209; 1938-0666
• DOI: 10.1016/j.clbc.2019.04.015

The B2 Prognostic Score (B2PS) is a clinical decision-making tool in metastatic breast cancer (MBC) that provides risk classification based on routine parameters. This study validates the B2PS in an independent series of MBC for the whole study group and for each intrinsic subtype.
We analyzed 641 metastasized patients, treated in 17 German certified breast cancer centers between 2001 and 2009. They were classified into low, intermediate, and high-risk groups according to B2PS. Overall survival (OS) curves for the various B2PS groups were compared with Kaplan-Meier method.
According to the B2PS formula, 42.3% of patients were classified as low risk, 25.4% as intermediate risk and 32.3% as high risk. Intermediate- and high-risk patients had a statistically significant decreased OS compared with B2PS low-risk patients: (intermediate-risk: hazard ratio, 1.36; 95% confidence interval, 1.04-1.77; P = .023; high-risk: hazard ratio, 2.62; 95% confidence interval, 2.06-3.32; P < .001). The 5-year survival rates of low-, intermediate-, and high-risk patients were 41.3%, 26.9%, and 10.2%, respectively. The distribution of B2PS risk groups varied significantly within the intrinsic subtypes. For each intrinsic subtype, B2PS gives an additional risk classification.
This study demonstrates the reproducibility of the B2PS based on routinely assessable parameters and confirms its prognostic value in an independent entire cohort of MBC as well as in the separate intrinsic subtypes. It therefore can help in counseling and individualizing the therapeutic regimens of those patients.
The B2 Prognostic Score (B2PS) is a decision-making tool in metastatic breast cancer. A total of 641 patients treated between 2001 and 2009 were classified into risk groups based on the B2PS, and survival parameters were compared. Intermediate- and high-risk groups showed decreased survival, and the distribution of risk groups varied within the intrinsic subtypes. The B2PS helps in counseling patients with metastatic breast cancer.